Involvement of Endocytosis in the Transdermal Penetration Mechanism of Ketoprofen Nanoparticles

Int J Mol Sci. 2018 Jul 23;19(7):2138. doi: 10.3390/ijms19072138.

Abstract

We previously designed a novel transdermal formulation containing ketoprofen solid nanoparticles (KET-NPs formulation), and showed that the skin penetration from the KET-NPs formulation was higher than that of a transdermal formulation containing ketoprofen microparticles (KET-MPs formulation). However, the precise mechanism for the skin penetration from the KET-NPs formulation was not clear. In this study we investigated whether energy-dependent endocytosis relates to the transdermal delivery from a 1.5% KET-NPs formulation. Transdermal formulations were prepared by a bead mill method using additives including methylcellulose and carbopol 934. The mean particle size of the ketoprofen nanoparticles was 98.3 nm. Four inhibitors of endocytosis dissolved in 0.5% DMSO (54 μM nystatin, a caveolae-mediated endocytosis inhibitor; 40 μM dynasore, a clathrin-mediated endocytosis inhibitor; 2 μM rottlerin, a macropinocytosis inhibitor; 10 μM cytochalasin D, a phagocytosis inhibitor) were used in this study. In the transdermal penetration study using a Franz diffusion cell, skin penetration through rat skin treated with cytochalasin D was similar to the control (DMSO) group. In contrast to the results for cytochalasin D, skin penetration from the KET-NPs formulation was significantly decreased by treatment with nystatin, dynasore or rottlerin with penetrated ketoprofen concentration-time curves (AUC) values 65%, 69% and 73% of control, respectively. Furthermore, multi-treatment with all three inhibitors (nystatin, dynasore and rottlerin) strongly suppressed the skin penetration from the KET-NPs formulation with an AUC value 13.4% that of the control. In conclusion, we found that caveolae-mediated endocytosis, clathrin-mediated endocytosis and macropinocytosis are all related to the skin penetration from the KET-NPs formulation. These findings provide significant information for the design of nanomedicines in transdermal formulations.

Keywords: endocytosis; ketoprofen; nanoparticle; pharmacological inhibitor; transdermal delivery system.

MeSH terms

  • Acetophenones / pharmacology
  • Administration, Cutaneous
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics*
  • Benzopyrans / pharmacology
  • Cells, Cultured
  • Cytochalasin D / pharmacology
  • Drug Liberation
  • Endocytosis*
  • Hydrazones / pharmacology
  • Ketoprofen / administration & dosage
  • Ketoprofen / pharmacokinetics*
  • Male
  • Nanoparticles / chemistry*
  • Nanoparticles / metabolism
  • Nystatin / pharmacology
  • Rats
  • Rats, Wistar
  • Skin / drug effects*
  • Skin / metabolism
  • Skin Absorption*

Substances

  • Acetophenones
  • Anti-Inflammatory Agents, Non-Steroidal
  • Benzopyrans
  • Hydrazones
  • N'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide
  • Nystatin
  • Cytochalasin D
  • Ketoprofen
  • rottlerin